GSK Korea Head Rebuffs Speculation About Hostile Takeover Of Dong-A

SEOUL - GlaxoSmithKline said it is not pursuing a hostile takeover of South Korea's leading drug firm Dong-A Pharmaceutical despite market speculation triggered when the multinational company bought 9.9 percent of Dong-A's equity in May